OCULAR THERAPEUTIX, INCOCUL
| Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | - | - | - | - | -60 | 86 | -156 | -7 | -71 | -81 | -194 |
|---|
| Share-based Compensation | 3 | 5 | 6 | 7 | 7 | 9 | 8 | 15 | 17 | 18 | 33 |
|---|
| Non-cash interest expense | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 5 | 5 | 6 | 4 |
|---|
| Change in fair value of derivative liabilities | - | - | - | - | - | - | - | - | - | -5 | -0 |
|---|
| Depreciation and amortization expense | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 4 |
|---|
| Gains and losses on extinguishment of debt, net | -0 | - | - | - | - | - | - | - | - | 14 | -28 |
|---|
| Gain on disposal of property and equipment | -0 | 0 | -1 | 0 | - | -0 | - | 0 | -0 | -0 | - |
|---|
| Accounts receivable | 0 | -0 | 0 | -0 | -0 | 2 | 10 | 9 | 0 | 5 | 6 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | -1 | -0 | 0 | 1 | 2 | 0 | -1 | 4 | 6 |
|---|
| Inventory | 0 | 0 | -0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
|---|
| Accounts payable | 1 | 0 | -0 | 1 | -1 | 0 | -0 | 2 | -1 | 1 | -0 |
|---|
| Operating lease assets | - | - | - | - | - | -1 | -1 | -1 | 3 | -2 | -1 |
|---|
| Accrued expenses | 2 | 0 | 1 | 3 | 2 | 2 | 2 | 4 | 2 | 1 | 4 |
|---|
| Deferred revenue | - | - | - | - | - | - | 12 | 1 | 1 | 0 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | -1 | -1 | -1 | 3 | -2 | -1 |
|---|
| Net cash used in operating activities | - | - | - | -50 | -49 | -78 | -54 | -66 | -60 | -70 | -135 |
|---|
| Purchases of property and equipment | 1 | 2 | 2 | 8 | 2 | 2 | 1 | 1 | 4 | 6 | 1 |
|---|
| Net cash used in investing activities | - | - | - | 27 | -2 | -2 | -1 | -1 | -4 | -6 | -1 |
|---|
| Proceeds From Issuance of Protective Advance | - | - | - | - | - | - | - | - | - | 2 | - |
|---|
| Proceeds from Notes Payable | 15 | 2 | - | 4 | 12 | - | - | 4 | - | - | - |
|---|
| Proceeds from Stock Options Exercised | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 1 | 1 | 15 |
|---|
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
|---|
| Payments of debt refinancing costs | - | - | - | - | - | - | - | - | - | 5 | - |
|---|
| Proceeds from Issuance of Common Stock | 70 | - | 1 | 29 | 62 | 38 | 225 | - | - | 117 | - |
|---|
| Repayment of MidCap notes payable | - | - | - | - | - | - | - | - | - | 26 | - |
|---|
| Repayment from issuance of short-term bridge loan | 2 | 2 | - | 1 | 6 | - | - | 4 | - | - | - |
|---|
| Proceeds from Issuance of Private Placement | - | - | - | - | - | - | - | - | - | - | 316 |
|---|
| Net cash provided by financing activities | - | - | - | 32 | 69 | 75 | 228 | 3 | 1 | 170 | 332 |
|---|
| Net increase in cash, cash equivalents and restricted cash | - | - | - | - | 18 | -4 | 174 | -64 | -62 | 94 | 196 |
|---|
| Interest Paid | - | - | - | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 22 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|---|